RCA
FBLG icon

Runnymede Capital Advisors’s FibroBiologics FBLG Stock Holding History

Runnymede Capital Advisors’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500
Closed -$5.46K – 122
2025
Q3 		$5.46K Buy
+500
New +$5.99K ﹤0.01% 70

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ANTB
AMG National Trust Bank Greenwood Village, Colorado $4.61B AUM 19.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Runnymede Capital Advisors's FBLG Position: Q4 2025 in Review

Runnymede Capital Advisors sold out of FibroBiologics (FBLG) in Q4 2025, closing a stake of 500 shares — an estimated $5.46K sold.

Runnymede Capital Advisors first reported a position in FBLG in Q3 2025 and held it in 1 quarter. The position peaked at $5.46K in Q3 2025. 45 funds tracked by Wall St. Rank hold FBLG as of Q4 2025.

  • Runnymede Capital Advisors reported no remaining FibroBiologics position as of Q4 2025 after selling out during the quarter.
  • Runnymede Capital Advisors sold 500 FibroBiologics shares in Q4 2025, an estimated $5.46K.
  • Runnymede Capital Advisors first reported a position in FibroBiologics in Q3 2025 and held it in 1 quarter.
  • Runnymede Capital Advisors's FibroBiologics position peaked at $5.46K in Q3 2025.
  • 45 funds tracked by Wall St. Rank held FibroBiologics as of Q4 2025.

Based on Runnymede Capital Advisors's 13F filing for Q4 2025, filed 21 Jan 2026.